MANGALAM · NSE
Mangalam Drugs And Organics Limited
₹31.65
-2.07% (-₹0.67)
Prev. close
₹32.32
Volume
33,768
Delivery %
74.2%
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Mangalam Drugs And Organics Limited
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol. Further, it offers organic and inorganic chemicals and heavy chemicals; and offers active pharmaceutical ingredients; and products covering various therapeutic areas comprising anti-malaria, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-convulsant, anti-viral, anti-rheumatic arthritis agents, and anti-bacterial, as well as develops product for anti-hypertensive indications. Mangalam Drugs & Organics Limited was incorporated in 1972 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Govardhan Murlidhar Dhoot
Headquarters
Mumbai
Employees
319
Website
mangalamdrugs.comExchange
View on NSE ↗Key stats
Market cap
₹50.10 Cr
EPS (TTM)
₹-24.16
Beta (1Y · daily vs NIFTY 50)
0.48
Beta (5Y · monthly vs NIFTY 50)
0.22
Shares float
93.31 L
EPS · quarter ended Jun 2026
₹-4.83
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 1.7% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹380.14 Cr | ₹451.07 Cr | ₹372.25 Cr | ₹368.59 Cr | ₹315.19 Cr | ₹232.13 Cr | |
| EBITDA | ₹58.02 Cr | ₹49.14 Cr | ₹22.12 Cr | ₹13.99 Cr | ₹32.57 Cr | ₹-18.07 Cr |
| ₹27.97 Cr | ₹19.66 Cr | ₹1.27 Cr | ₹-9.07 Cr | ₹6.72 Cr | ₹-44.40 Cr | |
| Diluted EPS | ₹17.67 | ₹12.42 | ₹0.8 | ₹-5.73 | ₹4.25 | ₹-28.05 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹264.11 Cr | ₹328.43 Cr | ₹359.63 Cr | ₹334.00 Cr | ₹366.00 Cr | ₹315.00 Cr | |
| — | — | ₹88.55 Cr | ₹105.64 Cr | ₹96.23 Cr | ₹112.75 Cr | |
| Stockholders' equity | — | ₹150.56 Cr | ₹151.96 Cr | ₹136.00 Cr | ₹149.00 Cr | ₹103.00 Cr |
Current assets, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹27.55 Cr | ₹30.70 Cr | ₹39.52 Cr | ₹3.91 Cr | ₹42.59 Cr | ₹4.18 Cr | |
| Investing cash flow | ₹-31.29 Cr | ₹-27.33 Cr | ₹-22.17 Cr | ₹-11.83 Cr | ₹-19.47 Cr | ₹-11.72 Cr |
| ₹2.70 Cr | ₹-2.01 Cr | ₹-16.62 Cr | ₹5.23 Cr | ₹-21.71 Cr | ₹5.66 Cr | |
| Capital expenditure | ₹-31.44 Cr | ₹-27.88 Cr | ₹-27.91 Cr | ₹-11.83 Cr | ₹-20.20 Cr | ₹-11.90 Cr |
| End cash position | ₹58.42 L | ₹1.95 Cr | ₹2.68 Cr | ₹1.18 Cr | ₹2.59 Cr | ₹70.10 L |
Dividends paid has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Mar 22(3Q) | Jun 22–Sep 22(2Q) | Dec 22–Jun 24(7Q) | Sep 24–Sep 25(5Q) | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|
| Promoter | 50.53% | 50.42% | 50.32% | 50.30% | 35.64% | 35.65% |
| Public | 49.47% | 49.58% | 49.68% | 49.70% | 64.36% | 64.35% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| Mangalam Drugs And Organics Limited | ₹51.16 Cr | ₹31.65 | — | 0.50 | -43.1% | 1.09 | -26.9% | -57.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 24
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Mangalam Drugs Yearly Results, Financial summary, Mangalam Drugs Yearly Earnings
Mangalam Drugs and Organics Ltd. reported a significant decline in its yearly financial results. Total income decreased by 26.93% to Rs 232.90 crore, and the company posted a net loss of Rs 43.81 crore, a 732.76% drop from the previous year. This performance reflects a challenging period for the pharmaceutical company.